F
F. Ivy Carroll
Researcher at Research Triangle Park
Publications - 301
Citations - 11139
F. Ivy Carroll is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Nicotinic agonist & Dopamine transporter. The author has an hindex of 52, co-authored 301 publications receiving 10411 citations. Previous affiliations of F. Ivy Carroll include RTI International & St. Joseph's Hospital and Medical Center.
Papers
More filters
Journal ArticleDOI
Epibatidine structure-activity relationships.
TL;DR: SAR studies directed toward epibatidine analogues will be reviewed, with a focus on alpha4beta2 nAChRs and its biological effects.
Journal ArticleDOI
Emergence and properties of spice and bath salts: A medicinal chemistry perspective
TL;DR: So-called "bath salts" largely contain synthetic analogs of the natural compound Khat; spice-related materials, claimed to be "legal marijuana," are mostly synthetic Analogs of cannabinoid receptor ligands that were developed as research tools.
Patent
Kappa opioid receptor ligands
TL;DR: Kappa opioid receptor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioids receptor such as heroin or cocaine addictions as discussed by the authors.
Journal ArticleDOI
Fluoro-norchloroepibatidine: preclinical assessment of acute toxicity.
Patricia E. Molina,Patricia E. Molina,Yu-Shin Ding,F. Ivy Carroll,F. Liang,Nora D. Volkow,Naomi Pappas,Michael J. Kuhar,Naji N. Abumrad,S. John Gatley,Joanna S. Fowler +10 more
TL;DR: The results suggest that it is not advisable to initiate human PET studies with [18F]-NFEP without further evidence supporting its safety, and further studies are needed to determine the safety of NFEP that are specifically designed to assess the catecholamine response.
Journal ArticleDOI
Bupropion increases striatal vesicular monoamine transport
Kristi S. Rau,Elisabeth Birdsall,Jarom E. Hanson,Kamisha L. Johnson-Davis,F. Ivy Carroll,Diana G. Wilkins,James W. Gibb,Glen R. Hanson,Annette E. Fleckenstein +8 more
TL;DR: Results revealed bupropion rapidly, reversibly, and dose-dependently increased vesicular DA uptake; an effect also associated with VMAT-2 protein redistribution, which demonstrated similarities and differences in the mechanism by which MPD and bupropions affect striatal dopaminergic nerve terminals.